Pharmaceutical company UCB will buy additional shares in the offering as Dermira, which is also backed by Maruho, seeks to raise funds for product development.
Dermira, a US-based developer of dermatology products, set the range for its initial public offering between $14 and $16 on Friday and will look to raise up to $98.4m when it floats.
A total of 5.35 million shares will be offered by the company in the IPO.
Dermira has raised approximately $128m since it was founded in 2010, including $51m in series C funding last month from pharmaceutical company UCB, Bay City Capital, New Enterprise Associates (NEA), Canaan Partners, Apple…
